Evidence map›Paper›PMID 26781785›Full record

ArticleClinical rheumatology2016

Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis.

Xiaomei Leng, Weiguo Xiao, Zhonghui Xu, Xiaochun Zhu, Yi Liu, Dongbao Zhao, Huji Xu, Guoqiang Chen, Wei Yu, Jing Lu and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 1 country.

Xiaomei LengDepartment of Rheumatology, Peking Union Medical College Hospital (West Campus), Chinese Academy of Medical Sciences, No. 41 Da Mu Cang, Western District, Beijing, 100032, China.
Weiguo XiaoThe First Hospital of China Medical University, Shenyang, China.
Zhonghui XuDepartment of Rheumatology, Peking Union Medical College Hospital (West Campus), Chinese Academy of Medical Sciences, No. 41 Da Mu Cang, Western District, Beijing, 100032, China.
Xiaochun ZhuThe First Hospital of Wenzhou Medical College, Wenzhou, China.
Yi LiuWest China Hospital, Sichuan University, Chengdu, China.
Dongbao ZhaoChanghai Hospital of Shanghai, Shanghai, China.
Huji XuShanghai Changzheng Hospital, Shanghai, China.
Guoqiang ChenThe First People's Hospital of Foshan, Foshan, China.
Wei YuDepartment of Rheumatology, Peking Union Medical College Hospital (West Campus), Chinese Academy of Medical Sciences, No. 41 Da Mu Cang, Western District, Beijing, 100032, China.
Jing LuThe First Hospital of China Medical University, Shenyang, China.
Jiakai WangThe First Hospital of China Medical University, Shenyang, China.
Xiaoru XiaThe First Hospital of Wenzhou Medical College, Wenzhou, China.
Yongji LiThe First Hospital of Wenzhou Medical College, Wenzhou, China.
Yi ZhaoWest China Hospital, Sichuan University, Chengdu, China.
Honghu TangWest China Hospital, Sichuan University, Chengdu, China.
Yeqing ShiChanghai Hospital of Shanghai, Shanghai, China.
Jun BaoShanghai Changzheng Hospital, Shanghai, China.
Ling ChenShanghai Changzheng Hospital, Shanghai, China.
Li LinShanghai Changzheng Hospital, Shanghai, China.
Ling ZhouShanghai Changzheng Hospital, Shanghai, China.
Hongwei ZhangThe First People's Hospital of Foshan, Foshan, China.
Yan ZhaoDepartment of Rheumatology, Peking Union Medical College Hospital (West Campus), Chinese Academy of Medical Sciences, No. 41 Da Mu Cang, Western District, Beijing, 100032, China. zhaoyan_pumch2002@126.com.
Shanghai Changzheng Hospital · CNPeking Union Medical College Hospital · CNWest China Hospital of Sichuan University · CNChina Medical University · CNFirst People's Hospital of Foshan · CNSecond Military Medical University · CNWenzhou Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Wenzhou Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with rheumatoid arthritis (RA). Eighty-two RA patients were recruited and followed up for 22 weeks. The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinations were performed at baseline, 6, 14, and 22 weeks after infliximab treatment. GSUS for synovitis and PDUS for synovitis and paratendinitis/tenosynovitis were assessed by a semi-quantitative (0 to 3) score, while GSUS for paratendinitis/tenosynovitis and bone erosion was qualitatively assessed as absent or present (0 or 1). US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. After 6, 14, and 22 weeks of treatment with infliximab, indices such as US scores, 28-joint disease activity (DAS28) score, and tender and swelling joint count were all significantly improved compared to baseline. US7 scores were significantly correlated with that of US12. Strong correlations were identified between most US7 scores with DAS28, health assessment questionnaire (HAQ), and C-reactive protein (CRP) levels. When DAS28 was used as a reference, the US7 cutoff for disease remission was less than 35 for GS + PD and also less than 29 for GS and 1 for PD, respectively. Additionally, the positive percent agreement, negative percent agreement, and overall percent agreement for GS + PD were 77.78, 76.19, and 76.67 %, respectively, which were all higher than that of GS or PD. US7 may be a feasible tool to assess the therapeutic response in RA patients.

Indexed as

AdultAgedAntirheumatic AgentsArthritis, RheumatoidFemaleHand JointsHumansInfliximabMaleMiddle AgedSeverity of Illness IndexTreatment OutcomeUltrasonographyYoung AdultAntirheumatic AgentsInfliximabAnti-TNFαDisease activity assessmentGrayscale ultrasoundPower Doppler ultrasoundRheumatoid arthritis

Identifiers

PMID26781785
OpenAlexW2278696589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.